Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm ; 453(1): 253-84, 2013 Aug 30.
Article in English | MEDLINE | ID: mdl-22820134

ABSTRACT

Spray drying is an efficient technology for solid dispersion manufacturing since it allows extreme rapid solvent evaporation leading to fast transformation of an API-carrier solution to solid API-carrier particles. Solvent evaporation kinetics certainly contribute to formation of amorphous solid dispersions, but also other factors like the interplay between the API, carrier and solvent, the solution state of the API, formulation parameters (e.g. feed concentration or solvent type) and process parameters (e.g. drying gas flow rate or solution spray rate) will influence the final physical structure of the obtained solid dispersion particles. This review presents an overview of the interplay between manufacturing process, formulation parameters, physical structure, and performance of the solid dispersions with respect to stability and drug release characteristics.


Subject(s)
Drug Compounding/methods , Pharmaceutical Preparations/chemistry , Animals , Chemistry, Pharmaceutical , Desiccation/methods , Humans , Pharmacokinetics , Solubility , Technology, Pharmaceutical/methods , Water/chemistry
2.
Eur J Pharm Biopharm ; 81(3): 674-82, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22521332

ABSTRACT

Since only limited amount of drug is available in early development stages, the extruder design has evolved towards smaller batch sizes, with a more simple design. An in dept study about the consequences of the differences in design is mandatory and little can be found in literature. Miconazole and Kollicoat IR were used as model drug and carrier for this study. Two series of solid dispersions were made with a laboratory scale (internal circulation-simple screw design) and a pilot scale extruder (continuous throughput-modular screw design). Efforts were made to match the operating parameters as close as possible (residence time, extrusion temperature and screw speed). The samples were analyzed with modulated DSC straight after production and after exact 24h and 15 days storage at -26 °C. The kinetic miscibility of the samples prepared with the laboratory scale extruder was slightly higher than the samples prepared with the pilot scale extruder. As the solid dispersions with high drug load were unstable over time, demixing occurred, slightly faster for the samples prepared with the laboratory scale extruder. After 15 days, the levels of molecular mixing were comparable, pointing to the predictive value of samples prepared on laboratory scale.


Subject(s)
Drug Carriers/chemistry , Drug Compounding/methods , Miconazole/chemistry , Polyvinyls/chemistry , Calorimetry, Differential Scanning , Chemistry, Pharmaceutical/methods , Drug Stability , Drug Storage , Equipment Design , Hot Temperature , Miconazole/administration & dosage , Technology, Pharmaceutical/instrumentation , Technology, Pharmaceutical/methods , Time Factors
3.
Pharm Res ; 28(3): 673-82, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21104299

ABSTRACT

PURPOSE: To investigate the effect of the manufacturing method (spray-drying or hot-melt extrusion) on the kinetic miscibility of miconazole and the graft copolymer poly(ethyleneglycol-g-vinylalcohol). The effect of heat pre-treatment of solutions used for spray-drying and the use of spray-dried copolymer as excipient for hot-melt extrusion was investigated. METHOD: The solid dispersions were prepared at different drug-polymer ratios and analyzed with modulated differential scanning calorimetry and X-ray powder diffraction. RESULTS: Miconazole either mixed with the PEG-fraction of the copolymer or crystallized in the same or a different polymorph as the starting material. The kinetic miscibility was higher for the solid dispersions obtained from solutions which were pre-heated compared to those spray-dried from solutions at ambient temperature. Hot-melt extrusion resulted in an even higher mixing capability. Here the use of the spray-dried copolymer did not show any benefit concerning the kinetic miscibility of the drug and copolymer, but it resulted in a remarkable decrease in the torque experienced by the extruder allowing extrusion at lower temperature and torque. CONCLUSION: The manufacturing method has an influence on the mixing capacity and phase behavior of solid dispersions. Heat pre-treatment of the solutions before spray-drying can result in a higher kinetic miscibility. Amorphization of the copolymer by spray-drying before using it as an excipient for hot-melt extrusion can be a manufacturing benefit.


Subject(s)
Chemistry, Pharmaceutical/methods , Hot Temperature , Polyvinyls/chemical synthesis , Polyethylene Glycols/analysis , Polyethylene Glycols/chemical synthesis , Polymers/chemical synthesis , Solutions , Vinyl Compounds/chemical synthesis , X-Ray Diffraction/methods
4.
Eur J Pharm Biopharm ; 74(2): 239-47, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19782134

ABSTRACT

In order to fully exploit the graft copolymer poly(ethyleneglycol-g-vinylalcohol) (EG/VA) in the formulation of solid dispersions, a characterization of its phase behavior before, during and after spray-drying and hot-melt extrusion is performed. Solid state characterization was performed using MDSC and XRPD. The effect of heating/cooling rate on the degree of crystallinity was studied using HPer DSC and ultra-fast chip calorimetry. EG/VA consists of two semi-crystalline fractions, one corresponding to the polyethyleneglycol (PEG) fraction (T(g)=-57 degrees C, T(m)=15 degrees C) and one corresponding to the polyvinylalcohol (PVA) fraction (T(g)=45 degrees C, T(m)=212 degrees C). XRPD analysis confirmed its semi-crystallinity, and EG/VA showed Bragg reflections comparable to those of PVA. Spray-drying at a temperature lower than 170 degrees C resulted in amorphization of the PVA fraction, while after hot-melt extrusion at different temperatures, the crystallinity of this fraction increases. In both cases, the PEG fraction is not influenced. Plasticization of the amorphous domains of the PEG or PVA fraction of the copolymer was dependent on the type and concentration of plasticizer, suggesting that also other small organic molecules like drugs may not homogeneously mix with both amorphous domains. A controlled cooling rate of 3000 degrees C/s was necessary to make the copolymer completely amorphous.


Subject(s)
Drug Carriers/chemistry , Drug Compounding/methods , Polyvinyls/chemistry , Crystallization/methods , Drug Carriers/chemical synthesis , Plasticizers/chemistry , Polymers/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...